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Abstract Galactomannan (GM) is a polysaccharide pre-
sent in the cell wall of Aspergillus spp. that is released
during growth of the organism. It has been successfully
used to aide in the diagnosis of invasive aspergillosis
allowing for earlier recognition of disease compared to
conventional methods. Since its implementation in the
clinic as a diagnostic tool, GM has been used in experi-
mental models to measure therapeutic response. Several
clinical studies describe the prognostic value of GM.
Herein, we review the evidence supporting the utilization
of GM antigen as a biomarker to measure response to
systemic antifungal therapy.
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Introduction
Invasive aspergillosis (IA) causes significant morbidity and
mortality [1]. Treatment is complicated by the limited
number of antifungal classes and agents, antifungal drug
toxicity, an incomplete spectrum of antifungal activity, and
increasing incidence of antifungal resistance [2–6]. The
routine management of patients is usually complicated by
uncertainty in the diagnosis, delayed treatment and absence
of information on the appropriate duration of therapy. One
of the biggest hurdles in clinical care is the assessment of
the response to therapy at the bedside. Clinical signs and
symptoms are notoriously nonspecific, radiological abnor-
malities often worsen before improving and clinical
response to therapy occurs over weeks-to-months. Better
clinical and laboratory tools that enable the therapeutic
response to therapy to be followed would be a considerable
advance in the routine care of patients with IA. In addition,
objectively assessing clinical outcomes in therapeutic trials
of new antifungal drugs is difficult and could be improved
with the use of a biomarker such as galactomannan (GM).
Galactomannan is a polysaccharide present in the cell
wall of Aspergillus spp., and some other fungi [7]. It is
released by hyphae, which are the biologically invasive
forms of filamentous moulds. A commercial double-sand-
wich enzyme-linked immunosorbent galactomannan assay
(ELISA) is available to detect Aspergillus GM antigen in
body fluids. The assay uses a monoclonal IgM obtained
from rats following challenge with mycelial extracts from
Aspergillus spp. [7, 8]. The assay has become a standard of
care for the diagnosis of invasive disease in high risk
patients [9].
Herein, we review the literature on the use of GM as a
biomarker of therapeutic response both in experimental
models and in the treatment of patients infected with
Aspergillus spp. A review of the literature was completed
using a standard PubMed search for ‘‘galactomannan and
pharmacodynamics’’, ‘‘galactomannan and Aspergillus
spp.’’, ‘‘triazole and galactomannan’’, ‘‘echinocandin and
galactomannan’’, and ‘‘polyene and galactomannan’’.
Articles related to the use of GM as a marker of response to
treatment were reviewed.
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Structure and biology of galactomannan
Galactomannan is a polysaccharide cell wall component
that has a branched structure with a linear a mannan that
has a repeating mannose oligosaccharide unit [6Man-
a1–2Mana1–2Mana1–2Mana1] and short chains of b (1,5)
galactofuranose residues [7]. It is released from fungal
hyphae during growth in the extracellular material (i.e.
ethanol-precipitable material) as part of the chemical
breakdown in the cell as the hyphae grow (i.e. a metabolic
event) and not a result of mycelial lysis. Organisms that are
known to release GM include Aspergillus spp., Fusarium
spp., Scedosporium spp., Alternaria spp., Histoplasma spp.
and Penicillium spp. [10–14]. GM can be detected in serum
and other bodily fluids such as bronchoalveolar lavage
(BAL) and cerebrospinal fluid (CSF), and has been used to
support a diagnosis of IPA and cerebral aspergillosis,
respectively. There are no established cut-offs values for
GM from matrices outside of the serum.
Aspergillus releases GM as part of recycling process of
the cell wall during hyphal growth. GM measurement is
achieved by using sandwich enzyme-linked immunosor-
bent assay (ELISA), which detects galactomannan antigen
via binding to monoclonal antibody and the formation of a
monoclonal antibody-galactomannan-monoclonal anti-
body/peroxidase complex. A spectrophotometer is used to
determine the absorbance (optical density; OD) of the
samples. Serum samples are considered positive when the
GMI (OD) is C0.5 and negative when\0.5. GMI has no
units and if expressed as a ratio of the OD value of the
sample to the OD value of a standard sample containing
1 ng of GM. The test has a lower limit of detection of 1 ng/
mL. GM is utilized primarily as a diagnostic test; however,
evidence is increasing for its value as a prognostic test.
How is GM linked with the pathogenesis of IA
The release of GM correlates with the progression of dis-
ease and its resolution in experimental models of IA [15].
Figures 1 and 2 shows how GM levels change over time in
rabbits (Fig. 1) [16] and humans (Fig. 2a, b) (submitted for
publication). Clear trends are seen when an infection
responds to effective therapy. Levels of GM in the serum
correspond to the timing of tissue invasion and are an
integral measure of the mass of viable invading organisms.
GM can be detected as early as 12 h post inoculation,
which corresponds with hyphal invasion as determined
using histopathological techniques [15, 17]. Serum GM
levels continue to increase and eventually reach a plateau
as the ELISA assay is saturated and/or there is capacity
limitation of fungal growth following exhaustion of avail-
able nutrients. BAL GM concentrations are typically high
throughout the course of infection in experimental models.
Presumably this reflects hyphal growth in the airways and
does not necessarily imply invasion. The presence of GM
implies the presence of hyphae rather than conidia (the
latter do not liberate GM) and in this sense GM provides
slightly different information than culture and PCR from
samples from the airways, which may not necessarily dis-
tinguish the different fungal morphotypes.
The discordant kinetic profiles of GM in serum and BAL
suggest that the GM does not transverse the alveolar-capil-
lary bilayer or other biological barriers to any great extent.
Presumably its molecular weight (*20 kDa) [7] prevent
transgression even in the context of significant tissue dis-
ruption. The appearance of GM in the circulation therefore
represents angioinvasion rather than simple diffusion into
the bloodstream from contiguous areas of infection.
To describe the changes in GM after infection and after
exposure to systemic antifungal therapy, several PK–PD
mathematical models have been described. One such exam-
ple, a version of a logistic growth model, is provided below:
dXð1Þ
dt
¼ Kg  1 X 1ð Þ
POPMAX
 
 Xð1Þ ð1Þ
where Kg represents the growth constant and POPMAX
represents the theoretical maximum GM concentration.
Here, as the GM concentration reaches the maximum
value, growth decreases until eventually ceasing. To extend
this to include population PK modeling for the antifungal,
the following example equation has been used to describe
the relationship of the two together:
dX1
dt
¼ Ka  X1 ð2Þ
dX2
dt
¼ Ka  X1þ RateIV  Vmax
Km  V þ X2  X2 Kcp  X2
þ Kpc  X3
ð3Þ
Fig. 1 Galactomannan index over time in rabbits treated in an
experimental model of invasive pulmonary aspergillosis infection [16]
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dX3
dt
¼ Kcp  X2 Kpc  X3 ð4Þ
dX4
dt
¼ KGMprod  1 X4
POPmax
  
 1
X2H
V
ECH50 þ X2
H
V
 !
 X4 KGMelim  X4
ð5Þ
where Eqs. 2–4 describe the flow of drug and Eq. 5
describing the relationship of drug and galactomannan
production and elimination.
Early in vivo studies suggest that the major pathway for
Aspergillus GM clearance from the bloodstream is renal
excretion and hepatic metabolism based on uptake by
macrophage mannose receptors [18]. The majority of the
renal excretion is rapid, within the first 24 h. Detectable of
GM in the urine of patients with IA has been reported [19].
GM is a complementary measure of fungal burden
in experimental models of IA
The traditional measure of tissue burden obtained by
plating serial dilutions of tissue homogenates to agar does
not (in general) provide a useful measure of fungal burden.
There are several reasons for this. In some experimental
models, sampling at early time-points may not enable
conidia (environmental forms) that are used to initiate
infection to be distinguished from hyphae (tissue invasive
forms). Detection of both morphotypes leads to a positive
Fig. 2 Observed
galactomannan index values
over time in patients with
invasive aspergillosis who were
alive after 42 days of treatment
(a) and those patients that did
not survive to day 42 (b), (data
on file)
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culture or PCR signal and quantification of fungal burden
even though it is only hyphae that are biologically relevant
in this situation. An accurate quantification of fungal bur-
den is further complicated by the growth patterns of
Aspergillus, which extends via hyphal elongation with
indistinguishable cellular units and additional branching
from older and newer segments [20]. Tissue homogeniza-
tion and quantitative counts do not enable an accurate
estimate of the fungal biomass. Propagules are either
incompletely separated or more vigorous grinding leads to
complete hyphal disruption and subsequent fungal death. In
either situation log10CFU/g is an inaccurate reflection of
the underlying fungal biomass and neither reflects impor-
tant events in the pathogenesis nor response to antifungal
therapy.
Despite these potential limitations, fungal burden
(log10CFU/g) from the rabbit model provides a crude, but
reliable readout to assess a variety of antifungal agents
(with the possible exception of the echinocandins). In this
model sampling occurs late in the treatment period and is
probably not confounded by the presence of conidia. In
other model systems, log10CFU/g is completely non-in-
formative. In any context log10CFU/g is often too impre-
cise to construct detailed dose–exposure–response
relationships.
Other non-culture techniques used to estimate fungal
burden in experimental models after infection with
Aspergillus spp. include polymerase chain reaction (PCR)
to measure of the amount of fungal DNA in tissues, or
assays that measure the amount of fungal cell wall com-
ponents such as chitin and 1,3-b-D-glucan. Each method
has advantages and limitations (see Table 1).
GM and experimental pharmacodynamics
GM is increasingly used in pharmacodynamic models of IA
to estimate dose-exposure-response relationships. The
advantages of this biomarker include a rapid response to
antifungal therapy, the fact it is readily quantifiable, the
availability of a commercial kit and validation in a variety
of model systems. The disadvantages include a relatively
narrow dynamic range, relatively high expense, and large
inherent variability.
Does serial GM kinetics and response differ by drug
class?
GM kinetics may differ according to drug class. With the
possible exception of the echinocandin agents, a decline in
GM occurs in a drug exposure-dependent manner
[16, 21–24]. Circulating GM may be paradoxically higher
following exposure of Aspergillus to all three of the
licensed echinocandin agents (i.e. caspofungin, micafungin
and anidulafungin). Combination with other antifungal
agents may be necessary to elicit a sufficient and sustained
decline in GM index (GMI) [25–27]. This paradoxical
effect is probably a result of the unique mechanism of
action of the echinocandins, which induce grossly aberrant
Table 1 Comparison of experimental techniques to measure Aspergillus fungal burden
Method Description Advantage Disadvantage
CFU Counting of single organisms by plating of
serial dilutions of a suspension; using a
hemacytometer
Simple, inexpensive Homogenation by mechanical dispersion can
disrupt the count by breaking the hyphae
into smaller pieces causing either fewer
viable fragments or increase in viable units
Chitin-
assay
Measure of the amount of chitin by KOH
extraction and colorimetric assay of an
aldehyde derivative of chitosan
Measuring content in hyphae not
conidia since chitin is not
present in conidia
Does not distinguish between viable and non-
viable hyphae, nor viable but ungerminated
conidia can go undetected.
PCR Measure either 18S rDNA (present in the
genome in 100 per nucleus) or FKS1,
single-copy gene
Better accuracy than CFU
depending on the tissue
especially in the first few days
after inoculation
Does not distinguish between viable and non-
viable organisms. Use of 18S rDNA can
over-estimate fungal burden given the
multinucleic nature of Aspergillus spp.
High cost, complex
Lateral-
flow
device
Detects the presence of Aspergillus-specific
MAb (JF5) [58]
Rapid detection of the presence
Aspergillus spp. within an
immune-chromatographic
lateral-flow device.
Measure of growing Aspergillus
No quantitative details of the amount of
organisms
Electronic
nose
Detects volatile organic compounds (VOCs)
using an ‘‘electronic nose’’ which is an
artificial olfactory system to discriminate
odors using an array of sensors [59]
Rapid detection of presence of
Aspergillus spp. in the airways
No quantitative details of the amount of
organisms
Only pertinent to pulmonary infection
CFU colony-forming units, KOH potassium hydroxide, PCR polymerase chain reaction, rDNA recombinant deoxyribonucleic acid
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branching of hyphae that impairs the ability of the organ-
ism to invade tissues. The organism is not killed, but
changes to the cell wall result in excessive liberation of
galactomannan. Thus there is de-linkage of the PK–PD
relationships when GM is used to assess the response to
echinocandin therapy.
A decline in GM in rabbits infected with A. fumigatus
after treatment with triazole antifungal agents is not evident
until after 4 to 6 days of treatment. In contrast, polyenes
demonstrate a more rapid response within the first two days
of therapy [21, 22, 28]. There are further idiosyncrasies
related to the various amphotericin B formulations. The
dosage (on a mg-mg basis) required to induce a decline in
GM is strikingly different amongst the clinically licensed
compounds (i.e. liposomal amphotericin B (LAMB)[ am-
photericin B lipid complex (ABLC)[ amphotericin B
deoxycholate (DAmB)) [29]. This is likely a function of the
thermodynamics that governs the transfer of active drug
from the micelle (DAmB) or lipid carrier (ABLC and
LAmB).
Do GM changes differ by Aspergillus species?
Studies evaluating non-Aspergillus fumigatus or A. fumi-
gatus with CYP51A mutations indicate that there are dif-
ferences among species with regard to response to therapy
and behavior in the model that limit generalizations across
Aspergillus species. A decline of GM is most dramatic with
A. fumigatus, followed by A. flavus and A. terreus [30–32].
In A. terreus-infected animals, the rate of increase of GM
post inoculation are slower than that of A. fumigatus [33].
This probably reflects significant differences in the rate and
extent of germination in the first 24 h in A. terreus com-
pared to A. fumigatus. In the first 8 h, less than 1.5% of the
A. terreus conidia germinate compared to 97% of A.
fumigatus.
The minimum inhibitory concentration (MIC) generally
affects exposure response relationships [34–39]. This has
been demonstrated repeatedly in pharmacodynamic studies
of triazole agents when testing multiple organisms over a
range of MICs [36, 40, 41]. Even in the presence of
mutations in the cellular target, response can be demon-
strated when exposures above the PD target are achieved
and this is can be predicted by the MIC values of the
organisms.
GM as a clinical biomarker with prognostic value
Clinical evidence supporting the utility of GM as a prog-
nostic tool for patients with IA has steadily accrued over
the past two decades. The earliest suggestion that GM
might be a valuable biomarker for measuring therapeutic
response in patients was established in 1997. However, the
general utility of exploiting the prognostic value of GM
was initially limited by the relatively high number of false
positive results [42]. In addition, early case reports describe
increasing GMI during treatment in individual patients
with poor outcomes. [43–45].
Evidence from case series and clinical studies
The first clinical study conducted early in the use of GM
was limited by sparse sampling. However, a trend of
increasing GM in patients that subsequently died was
evident [42]. Subsequently, nine separate studies repre-
senting 661 patients and one meta-analysis covering 27
studies and 257 patients that evaluated the utility of GM
assay to monitor therapeutic response have been reported.
Eight studies largely focused on patients with hematolog-
ical malignancy, while one included patients with COPD.
The studies evaluate responses in patients with proven,
probable, possible, or suspected IA and one study included
patients with invasive fusariosis. One study assesses the
use of serial GM in pediatric patients and the associated
exposure-response relationship. Each study demonstrates
the potential usefulness of serial GM measurements in IA
patients by showing that GM generally increases (or does
not decline) in patients that fail treatment or ultimately die.
Correlation with traditional measures of response
to therapy
Changes in GMI from the time of diagnosis or baseline
correlate significantly with various outcome measures
including clinical outcome defined by EORTC/MSG cri-
teria at 6 and 12 weeks, mortality at 12 weeks, and with
autopsy findings [46–49]. The GMI-based outcome pro-
posed from these correlations is defined as GMI negativity
(OD\ 0.5) for at least 2 weeks after the first positive value
without new pulmonary or extra-pulmonary lesions and
lack of findings of IA on autopsy [46, 47]. Figure 3 pro-
vides an illustration of survival trends for neutropenic
patients with positive (OD C 0.5) versus negative
(OD\ 0.5) GMI.
GMI-based outcome criteria—are we there yet?
Several outcome measures for GM are possible and include
time to GMI negativity, time to a certain percent reduction
in GMI, rate of decline (or GM decay), area under the GMI
time curve, or time to negativity. However, with all of
these possibilities, a degree or quantification of GMI
change aside from negativity has yet to be defined. The
only criterion that is currently used is GMI negativity
(OD\ 0.5) for a period of 2-weeks without pulmonary or
extra-pulmonary lesions. An autopsy may be necessary to
J Pharmacokinet Pharmacodyn
123
definitively exclude IA. While this GM outcome provides
excellent correlation to clinical measures of response, the
average time to negativity in one study was 21 days in
patients who ultimately responded to antifungal therapy.
An earlier intervention may be preferable [47]. The rate of
decline of GM (i.e. slope) at 1 week after diagnosis of IA
has also been proposed as a surrogate for clinical outcome
(i.e. for 6- and 12-week all-cause mortality) based on
increasing hazard ratios with each unit increase from
diagnosis [50]. This GM outcome measure is more prac-
tical than the GM outcome of negativity for 2 weeks
duration as it utilizes an early time point and relatively
simple calculation to guide response.
Significant increases in GM after each week of therapy
are associated with ultimate treatment failure [51–53].
Most studies report a strong correlation of survival with
decreases GMI (e.g. GMI normalization to readings\0.5)
[46, 48]. However, at least one study reports that changes
from baseline to week 2 are not predictive of 12-week
survival [52]. The reason is most likely because mortality
by 12 weeks is more often driven by underlying co-mor-
bidities as opposed to the fungal infection.
Other fungal biomarkers, such as, the 1,3-b-D-glucan
(BDG) assay (FungitellTM), are used in the clinic. BDG
detects the cell wall component (1,3)-b-D-glucan, which is
present in most fungi, and therefore, not specific to
Aspergillus spp. This assay could potentially be used in
conjunction with GM as a prognostic tool after IA is
diagnosed. However, there is little data available showing
correlation to clinical outcome outside of experimental
models [17, 54]. One study suggests that decline in the
mean time-weighted averages of BDG plus GM from
baseline to week 2 of therapy is associated with 6-and
12-week survival [53].
Using GM to individualize antifungal therapy
The time course of GM in an individual patient may be
affected by antifungal drug exposure (pharmacokinetics),
the MIC of the invading fungal pathogen, the immune
Fig. 3 Adapted from Maertens et al. [46] demonstrating the survival of 70 neutropenic patients with IA according to serum GMI
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status of the host, and the underlying high fungal burden
(pharmacodynamics). Therapeutic drug monitoring of
antifungal agents has traditionally focused on achieving
plasma drug exposure targets. The pharmacodynamic
responses to antifungal therapy have typically been less
formal. However, GM can potentially be used to guide
antifungal therapy at an individual level. The time course
of GM may provide a guide as to the intensity of antifungal
therapy that is required to achieve a favorable clinical
outcome. Patients with high unremitting GM concentra-
tions receiving a standard antifungal regimen should have
the dosage increased, the drug changed or a combination of
agents used. The necessary mathematical models that
explicitly link dosage, plasma drug concentrations and
circulating GM provide a way that therapy can be indi-
vidualized to move the biomarker rather than merely
achieving a target plasma concentration, which may not be
optimal for the patient.
A further possibility that is enabled by GM is an esti-
mate of the pharmacodynamic targets required for a
successful outcome. Traditionally, this pharmacodynamic
measure has been the MIC and drug exposure (e.g. AUC)
has been optimized with reference to this in vitro measure
of potency. A common problem in clinical mycology is
that the organism (and therefore the MIC) is not available-
it is quite uncommon for patients to have positive cul-
tures. The use of linked PK–PD models with GM as a
real-time pharmacodynamic readout provides alternative
measures of in vivo potency that can be used to optimize
drug exposure. The EC50 is the concentration of antifun-
gal drug that is required to induce half maximal antifungal
activity. The AUC can be optimized in relation to the
EC50 to secure a favorable outcome. This idea was
explored in a recent relatively small study in pediatric
patients receiving voriconazole [55]. In these children an
(AUC:EC50)/15.4 is significantly associated with terminal
GMI (GMI value at the end of therapy). When the ratio is
[6, the terminal GM tends to be lower. However, survival
did not correlate with the AUC:EC50. Further work is
ongoing in this area.
Evidence for GM beyond Aspergillus spp.
and hematological malignancies
Moulds other than Aspergillus spp. also release GMI. One
study describing 18 patients diagnosed with invasive
fusariosis shows a median time to GMI negativity of
14 days from the first positive GMI [56]. However, there
was no relationship between the time to GM negativity and
the 90-day outcome. In non-hematology patients, data for
the use of GMI as a prognostic marker is sparse. One study
in COPD patients showed that in non-survivors GMI is
higher ([0.5) in the first week [57], but there was a very
high rate of false positive results. There remains a paucity
of evidence for the use of GMI to follow the course of
disease beyond Aspergillus spp. and outside the hemato-
logical malignancy population.
Conclusions
GMI is an important experimental and monitoring tool in
the management of patients with IA. Critical steps to
establish the clinical utility of this biomarker continue to be
made. However, more work is needed in patients to better
define ways of using GMI early in the treatment course to
facilitate therapeutic decisions that can be beneficial for an
individual patient. As evidence accumulates, it is likely that
GM will be incorporated into clinical outcome criteria and
can therefore be used to assess the response to antifungal
therapy for future clinical trials.
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